Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile.

Diego A Díaz-Dinamarca,Pablo Díaz, Gisselle Barra,Rodrigo Puentes,Loredana Arata, Jonnathan Grossolli, Boris Riveros-Rodriguez, Luis Ardiles, Julio Santelises, Valeria Vasquez-Saez,Daniel F Escobar, Daniel Soto, Cecilia Canales,Janepsy Díaz,Liliana Lamperti,Daniela Castillo, Mychel Urra,Felipe Zuñiga,Valeska Ormazabal,Estefanía Nova-Lamperti, Rosana Benítez, Alejandra Rivera,Claudia P Cortes,María Teresa Valenzuela,Heriberto E García-Escorza,Abel E Vasquez

Frontiers in public health（2023）

引用 0|浏览21

暂无评分

摘要

These findings suggest that vaccination induces the secretion of antibodies against SARS-CoV-2, and a booster dose of BNT162b2 is necessary to generate a protective immune response. In the current state of the pandemic, these data support the Ministry of Health of the Government of Chile's decision to promote heterologous vaccination as they indicate that a significant portion of the Chilean population has neutralizing antibodies against SARS-CoV-2.

查看译文

关键词

SARS-CoV-2, Chilean vaccination, SARS-CoV-2 neutralizing antibodies, COVID19, BNT162b2 (Pfizer-BioNTech), CoronaVac vaccine, heterologous vaccination, immunization schedules

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要